Y Ibritumomab Tiuxetan: A Viewpoint by Ted Wun

Author： Wun T.  

Publisher： Adis International

ISSN： 1175-6357

Source： American Journal of Cancer, Vol.1, Iss.5, 2002-01, pp. : 349-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Y Ibritumomab Tiuxetan

By Carswell C.I.   Wiseman L.R.  

American Journal of Cancer, Vol. 1, Iss. 5, 2002-01 ,pp. : 341-348

Adis International

Access to resources Recommend Favorite

Salvage therapy for primary central nervous system lymphoma with 90Y-Ibritumomab and Temozolomide

By Pitini Vincenzo   Baldari Sergio   Altavilla Giuseppe   Arrigo Carmela   Naro Claudia   Perniciaro Francesca  

Journal of Neuro-Oncology, Vol. 83, Iss. 3, 2007-07 ,pp. : 291-293

Springer Publishing Company

Access to resources Recommend Favorite

Capecitabine: A Viewpoint by Werner Scheithauer

By Scheithauer Werner  

American Journal of Cancer, Vol. 4, Iss. 5, 2005-01 ,pp. : 324-325

Adis International

Access to resources Recommend Favorite

Bevacizumab: A Viewpoint by Richard M. Goldberg

By Goldberg Richard M.  

American Journal of Cancer, Vol. 3, Iss. 3, 2004-01 ,pp. : 195-196

Adis International

Access to resources Recommend Favorite

Erlotinib: A Viewpoint by Natasha B. Leighl

By Leighl Natasha B.  

American Journal of Cancer, Vol. 4, Iss. 4, 2005-01 ,pp. : 253-254

Adis International

Access to resources Recommend Favorite